Pfizer says it could seek COVID-19 vaccine emergency authorization in November

Pfizer could apply for emergency use authorization for its potential COVID-19 vaccine next month, its CEO says.
Pfizer CEO Albert Bourla on Friday provided an update on when the company may potentially seek emergency use authorization from the Food and Drug Administration for its coronavirus vaccine candidate, should it prove to be safe and effective.
"In the instance of emergency use authorization in the U.S. for a potential COVID-19 vaccine, FDA is requiring that companies provide two months of safety data on half of the trial participants following the final dose of the vaccine," Bourla explained. "Based on our current trial enrollment and dosing pace, we estimate we will reach this milestone in the third week of November."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Bourla added that "assuming positive data, Pfizer will apply for emergency authorization use in the U.S. soon after the safety milestone is achieved in the third week of November."
With this announcement, The New York Times noted that Pfizer was "ruling out President Trump's assertion that a vaccine would be ready before Election Day." The CEO of Moderna, another company that has a potential COVID-19 vaccine in development, recently told the Financial Times it would likely not have enough data to seek FDA emergency use authorization until at least Nov. 25. At the time of those comments, the Financial Times wrote that this meant that Trump's "most realistic hope of a pre-election vaccine" would be from Pfizer.
Bourla also reiterated on Friday that Pfizer may know whether its vaccine is effective by the end of October, although the data required to make this determination "may come earlier or later based on changes in the infection rates."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths